A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (RCTS) OF EGFR-TARGETED MONOCLONAL ANTIBODY (MAB) THERAPY IN ADVANCED COLORECTAL CANCER (ACRC): IMPACT OF K-RAS STATUS

A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (RCTS) OF EGFR-TARGETED MONOCLONAL ANTIBODY (MAB) THERAPY IN ADVANCED COLORECTAL CANCER (ACRC): IMPACT OF K-RAS STATUS

Detalhes bibliográficos
Main Authors:	Vale, C, Tierney, J, Meade, A, Fisher, D, Kaplan, R, Adams, R, Maughan, T, Parmar, M
Formato:	Journal article
Publicado em:	2009

Registos relacionados

Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
Por: Vale, C, et al.
Publicado em: (2009)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
Por: Maughan, T, et al.
Publicado em: (2010)

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
Por: Maughan, T, et al.
Publicado em: (2009)

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.
Por: Vale, C, et al.
Publicado em: (2012)

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
Por: Vale, C, et al.
Publicado em: (2012)

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS
Por: Adams, R, et al.
Publicado em: (2009)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
Por: Wasan, H, et al.
Publicado em: (2011)

HIGH THROUGHPUT SOMATIC PROFILING OF THE RAS-RAF-MAP AND PI3K-PTEN-AKT PATHWAYS IN ADVANCED COLORECTAL CANCER AND CORRELATIONS WITH RESPONSE TO CETUXIMAB
Por: Smith, C, et al.
Publicado em: (2010)

FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS and NRAS
Por: Adams, R, et al.
Publicado em: (2016)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Por: Beth O. Van Emburgh, et al.
Publicado em: (2016-12-01)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
Por: Adams, R, et al.
Publicado em: (2009)

Design and development of information portal for Asian Communication Resource Centre (ACRC).
Por: Yohanes Ramli.
Publicado em: (2008)

Limited Efficacy of Anti-EGFR Monoclonal Antibodies in Colorectal Cancer Patients with Rare RAS Variants: Analysis of the C-CAT Database
Por: Shuhei Suzuki, et al.
Publicado em: (2024-12-01)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
Por: Wood, G, et al.
Publicado em: (2017)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
Por: Maughan, T, et al.
Publicado em: (2010)

Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Por: Xiaona Lu, et al.
Publicado em: (2023-11-01)

CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?
Por: Thiago David Alves PINTO, et al.
Publicado em: (2021-06-01)

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
Por: Susan D. Richman, et al.
Publicado em: (2011-01-01)

Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
Por: Chen DT, et al.
Publicado em: (2019-02-01)

A phase I study of Tc-99m-h-R3 monoclonal antibody (DiaCIM (R)), a humanized monoclonal antibody (mAB) for imaging EGFR-positive malignancies.
Por: Reilly, R, et al.
Publicado em: (2002)

HUMANIZED MONOCLONAL-ANTIBODY (MAB) THERAPY FOR WEGENERS GRANULOMATOSIS (WG)
Por: Lockwood, C, et al.
Publicado em: (1995)

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
Por: Adams, R, et al.
Publicado em: (2017)

EGFR FISH analysis in colorectal cancer as a tool in selecting patients for antiEGFR monoclonal antibodies therapy
Por: Mauro Moroni, et al.
Publicado em: (2011-12-01)

IMGT/mAb-KG: the knowledge graph for therapeutic monoclonal antibodies
Por: Gaoussou Sanou, et al.
Publicado em: (2024-06-01)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
Por: Madi, A, et al.
Publicado em: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
Por: Madi, A, et al.
Publicado em: (2012)

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS
Por: Adams, R, et al.
Publicado em: (2010)

Multispecificity of a recombinant anti-ras monoclonal antibody
Por: Schrader, John W., et al.
Publicado em: (2017)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
Por: Maughan, T, et al.
Publicado em: (2010)

Essay 4. What kinds of efficacies evade randomised controlled trials (RCTs)?
Por: Alford, M
Publicado em: (2017)

Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras
Por: Samantha I. Liang, et al.
Publicado em: (2018-03-01)

Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB
Por: Taciana Manso, et al.
Publicado em: (2023-05-01)

Radiolabeling and biodistribution of monoclonal antibody (MAb) anti-CD20 with iodine-131
Por: Akinkunmi Ganiyu Akanji, et al.
Publicado em: (2005-10-01)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
Por: Adams, R, et al.
Publicado em: (2008)

A NOVEL COLORECTAL CANCER SUSCEPTIBILITY SNP IN THE EIF3H PROMOTER INFLUENCES PATIENT SURVIVAL AND RESPONSE TO TREATMENT
Por: Cheadle, J, et al.
Publicado em: (2010)

Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework
Por: Wilson, C, et al.
Publicado em: (2018)

Epitope mapping of an anti-diacylglycerol kinase delta monoclonal antibody DdMab-1
Por: Masato Sano, et al.
Publicado em: (2020-12-01)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Por: Adams, R, et al.
Publicado em: (2011)

The use of healthcare systems data for RCTs
Por: Alice-Maria Toader, et al.
Publicado em: (2024-01-01)

<it>EGFR</it> gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis
Por: Yang Zu-Yao, et al.
Publicado em: (2012-08-01)